乳腺癌人表皮生长因子受体2超低表达情况分析

Analysis of ultralow expression of human epidermal growth factor receptor 2 in breast carcinoma

目的探讨HER2免疫组化染色(IHC)检测结果为0乳腺癌中HER2超低表达情况。方法回顾性分析2021年1月至2022年12月安阳市肿瘤医院确诊为HER2 IHC检测结果为0乳腺癌样本107例,通过IHC检测HER2蛋白表达情况,根据HER2超低表达判断标准对结果判读。结果107例既往HER2 IHC检测判读为0的病例中,本次检测有7例被判读为1+,其中根治术样本6例、穿刺样本1例,IHC检测结果为0的样本100例。100例HER2 IHC检测结果为0样本中,HER2超低表达56例,阴性表达44例。HER2 IHC检测结果为0样本中,根治术样本超低表达率55.17%(48/87),穿刺术样本超低表达率61.54%(8/13),差异无统计学意义(χ^(2)=0.186,P=0.667)。HER2 IHC检测结果为0样本中,存在淋巴结转移的样本超低表达率48.00%(12/25),无淋巴结转移样本超低表达率58.67%(44/75),差异无统计学意义(χ^(2)=0.866,P=0.352)。结论乳腺癌中HER2的超低表达在HER2 IHC检测判读为0的样本中发生率较高,且与手术方式及淋巴结转移情况无关。

Objective To investigate the ultralow expression of human epidermal growth factor receptor 2(HER2)in patients with HER20 breast cancer.Methods The 107 breast cancer specimens collected in the from January 2021 to December 2022.The expression of HER2 was detected by using immunohistochemistry(IHC).The HER2 expression was assessed according to the HER2 ultralow expression standard.Results Among the 107 cases that were previously detected as HER2 IHC 0,7 were assessed as 1+,including 6 radical resection samples and 1 biopsy sample,and IHC 0100 cases.Among the 100 HER2 IHC 0 samples,56 had HER2 ultralow expression and 44 had HER2 null.The HER2 ultralow expression rate of radical resection samples was 55.17%(48/87),the biopsy samples of 61.54%(8/13),and the difference was not statistically significant(χ^(2)=0.186,P=0.667).The HER2 ultralow expression rate of lymph node metastasis samples was 48.00%(12/25)and the rate of no lymph node metastasis samples was 58.67%(44/75),and the difference was not statistically significant(χ^(2)=0.866,P=0.352).Conclusion The HER2 ultralow expression is more common in HER20 breast cancer,and there is no correlation with surgical methods and lymph node metastasis.